Form 4: STERIS Director Acquires Stock Options, RSUs

STERIS plc Director Esther M. Alegria acquired 1,407 nonqualified stock options and 487 career restricted stock units, effective August 8, 2025.

Summary

• Director Esther M. Alegria acquired 1,407 nonqualified stock options.
• The options have an exercise price of $242.85 per share.
• These options are fully vested and immediately exercisable as of August 8, 2025, and will expire on August 8, 2035.
• Additionally, 487 Career Restricted Stock Units (RSUs) were acquired.
• These RSUs are fully vested immediately as of August 8, 2025, and will be settled in STERIS ordinary shares six months after the cessation of Director Alegria's Board service.
• Following these transactions, Director Alegria beneficially owns 1,407 shares via stock options and a total of 2,896 Career Restricted Stock Units.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is generally positive as it aligns insider interests with shareholders. There are no negative disclosures or red flags.

Positives

• The Director's acquisition of stock options and RSUs aligns her interests with those of shareholders.
• The immediate vesting of both the options and RSUs indicates a direct grant of equity, providing immediate beneficial ownership.

Risks

• No specific risks related to the company's operations or financial health are detailed. The inherent market risk associated with holding equity applies.

Future Outlook

No forward-looking statements or guidance are provided beyond the vesting and settlement terms of the equity awards.

Industry Context

This Form 4 filing reflects routine insider equity compensation, which is a common practice across industries to align executive and director interests with shareholder value. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The specific details of equity grants, such as the number of options and RSUs, and their vesting schedules, are typical forms of director compensation.
• Without specific peer company compensation data, a direct comparison to industry benchmarks for similar roles at companies like Medtronic, Stryker, or Becton Dickinson is not possible based solely on this filing.
• The use of stock options and RSUs is standard practice in executive and director compensation packages across the healthcare and medical technology sectors.

Related Party Transactions

• The acquisition of stock options and restricted stock units by a director is considered a related party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value, potentially encouraging decisions that benefit the stock price.
• Employees: No direct impact on general employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• Settlement of Career Restricted Stock Units will occur six months after the cessation of the Director's Board service.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice aimed at aligning insider interests with shareholder value. It does not contain information that would fundamentally alter the investment thesis for STERIS plc, nor does it suggest any significant positive or negative catalysts. Therefore, an investor would likely maintain their current position based solely on this disclosure.

Keywords

STERIS plc, STE, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Executive Compensation